Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Related Questions
Do you prolong IV therapy or reduce the number of antibiotic agents for patients with pulmonary NTM infections who have completed induction IV therapy and cannot access oral antibiotic therapy due to cost?
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?
What additional treatment strategies would you recommend for a patient with a Mycobacterium chelonae and Mycobacterium abscessus infection following bilateral prophylactic mastectomies and implant insertion, who has undergone multiple surgeries and an extended course of IV antibiotics selected based on sensitivities?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
What are your top takeaways from ID Week 2024?
Do you recommend prescribing one or two parenteral antibiotics in addition to oral therapy in the management of Mycobacterium abscesses peritonitis related to peritoneal dialysis?
What agent and for how long would you treat a patient with asymptomatic azole-resistant C auris candiduria who is planning to undergo a urological procedure?
Do you give additional pneumococcal vaccines after a dose of PCV20 in patients with asplenia?
